Expression patterns of ER-α PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ

Annals of Clinical and Laboratory Science

Volumn 36, Issue 2, 2006, Pages 137-143

  Tang, Ping ^a   Wang, Xi ^a   Schiffhauer, Linda ^a   Wang, Jianmin ^a,b   Bourne, Patricia ^a   Yang, Qi ^a   Quinn, Andrew ^a   Hajdu, Steven ^a,c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Cell origin markers; Cytokeratins; Ductal carcinoma in situ; EGFR; ER ; HER 2 neu; Nuclear grade; PR

Indexed keywords

ANTIBODY; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BASAL CELL; BREAST CARCINOMA; BREAST DUCTAL CARCINOMA IN SITU; CARCINOMA IN SITU; CELL NUCLEUS; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; NULL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; UNITED STATES;

ADULT; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHI-SQUARE DISTRIBUTION; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; ONCOGENE PROTEINS V-ERBB; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PROGESTERONE;

EID: 33646529150     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004;96:906-920.
2. Ceilley E, Jagsi R, Goldberg S, Kachnic L, Powell S, Taghian A. The management of ductal carcinoma in situ in North America and Europe. Results of a survey. Cancer 2004;101:1958-1967.
3. Holland P, Petersen JL, Millis RR, Eusebi V, Faverly D, van de Vijver M, Zafrani B. Ductal carcinoma in situ: A proposal for a new classification. Semin Diagn Pathol 1994;11:167-180.
4. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, Lewinsky B, Gamagami P, Slamon DJ. Prognostic classification of breast ductal carcinoma in situ. Lancet 1995;345:1154-1157.
5. Silverstein MJ. The University of Southern California/ Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003;186:337-343.
6. Cornfield DB, Palazzo JP, Schwanz GF, Goonewarkdene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: A study of a large cohort of patients treated with surgery alone. Cancer 2004;100:2317-2327.
7. Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu S. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Ann Clin Lab Sci 2006;36:16-22.
8. Nagle RB, Bocker W, Davis JR, Heid HW, Kaufmann M, Lucas DO, Jarasch ED. Characterization of breast carcinoma by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 1986;34:869-881.
9. Jaracsh ED, Nagle RB, Kaufmann M, Maurer C, Bocker WJ. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Human Pathol 1988;19:276-289.
10. Tsubura A, Okada H, Senzaki H, Hatano T, Morii. Keratin expression in the normal breast and in breast carcinoma. Histopathology 1991;18:517-522.
11. Boecker W, Moll R, Dervan P, Buerger H, Poremba C, Diallo RI, Herbst H, Schmidt A, Lerch MM, Buchwalow IB. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 2002; 198:458-467.
12. Van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-1996.
13. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blarney RW, Robertson JF, Nicholson RI, Ellis IO. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-671.
14. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. Comparative genomic hybridization of ductal carcinoma in situ of the breast-Evidence of multiple genetic pathways. J Pathol 1999;187: 396-402.
15. Lacroix M, Toillon RA, Leclercq G. Stable "portrait" of breast tumors during progression: data from biology, pathology, and genetics. Endocrine-Related Cancer 2004;11:497-522.
16. Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocrine-Related Cancer 2004;11:391-406.
17. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;6l:5979-5984.
18. Shaaban AM, Jarvis C, Moore F, West C, Dodson A, Foster CS. Prognostic significance of estrogen receptor beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 2005;29:1593-1599.
19. Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor âin breast cancer. Cancer Chemother Pharmacol 2005;56(Suppl 1):s21-26.
20. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987;235:177-182.
21. Adb El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamney RW, Robertson JFR, Nicholson RI, Ellis IO. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004;91:1532-1542.
22. Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Phosphorated/ activated HER-2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest 2005;23:483-487.
23. Hudelist G, Kostler WJ, Czerwenka K, Kudista G, Attems J, Muller R, Gschwantlev-Kaulich D, Manavi M, Huber I, Hoschutzky H, Zielinski CC, Singer C. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer. 2006;118: 1126-1134.
24. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D II, Thor AD. Relationship of epidermal factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005, 23:1152-1160.
25. Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, Lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005;65:18-25.
26. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 2005;103:1770-1777.
27. Bianchi S, Palli D, Falchetti M, Saieva C, Masala G, Mancini B, Lupi R, Noviello C, Omerovic J, Paglierani M, Vezzosi V, Alimandi M, Mariani-Costantini R, Ottini L. ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study. J Cell Physiol 2006;206:702-708.
28. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev 2005;14:1008-1011.
29. Eppenberger-Castori S, Moore DH, Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 2002;34:1318-1330.